Why the study?
Does dabigatran etexilate reduce bleeding and thromboembolic complications compared to enoxaparin in patients undergoing intramedullary osteosynthesis for femur and tibia fractures?
Does dabigatran etexilate reduce bleeding and thromboembolic complications compared to enoxaparin in patients undergoing intramedullary osteosynthesis for femur and tibia fractures?
Dabigatran etexilate is a safe and effective alternative to enoxaparin for VTE prevention after intramedullary osteosynthesis of lower limb fractures, offering better compliance and fewer bleeding complications.
Answers are grounded in this paper and cite their sources.
Dabigatran was associated with fewer bleeding events after lower-limb fracture fixation; leaves open confirmation by randomized trials before practice change.
The results of application of dabigatran etexilate in treatment of 56 patients aged 60 to 89 with closed diaphyseal fractures of femur and tibia undergone intramedullary osteosynthesis were studied. The patients were divided into 2 groups. The first group consisted of patients receiving standard anticoaqulant therapy. The second one included patients who used etyek-silat (pradaxa OS) in early postoperative period. The results of treatment in these groups were analysed and compared. Evidence-based significant advantage of dabigatran etexilate (pradaxa R ) administration in early postoperative period was revealed.
No takes yet. Share an insight, caveat, or question.
Дулаев et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: